title: Weight and content uniformity of lorazepam half-tablets: A study of correlation of a low drug content product.
abstract: The aim of this study was to investigate the degree of correlation between the weight and the content of spilt-halves of lorazepam 2.5 mg tablets. Weight variation and drug content of lorazepam half-tablets were evaluated according to the European Pharmacopoeia tests. Only one individual mass of the 30 half tablets was outside the limits of 85-115% of the average mass, but since it was within 75-125% of the average mass, the product passed the test. Each individual content was between 85% and 115% of the average content (99.8% expressed as a percent to label claim) and within the limits of 75-125%, so the product passed the uniformity of content test. The correlation coefficient (r) between the weight and the content of split halves was found to be 0.994. The weights of split tablet halves appear to be directly correlated with their drug content even for a medication with a low drug content, thus it is recommended that pharmacists who split tablets into two halves, assure the weight uniformity of the resultant halves. Manufacturers should develop formulation and manufacturing procedures that ensure high degree of correlation between weight and content not only among the whole tablet but also among the obtained tablet halves.
authors: Department of Pharmacy, An-Najah National University, P.O. Box 7, Nablus, Palestine.
authors: Abdel Naser
authors: AN
authors: Zaid
authors: Rowa' J
authors: RJ
authors: Al-Ramahi
authors: Abeer Abu
authors: AA
authors: Ghoush
authors: Aiman
authors: A
authors: Qaddumi
authors: Yara Abu
authors: YA
authors: Zaaror
keywords: Content; Lorazepam; Splitting; Uniformity; Weight
references: Am J Health Syst Pharm. 1999 Dec 15;56(24):2542-5
references: 10613374
references: Bosn J Basic Med Sci. 2007 Nov;7(4):328-34
references: 18039191
references: Pharm World Sci. 2003 Aug;25(4):173-6
references: 12964497
references: PDA J Pharm Sci Technol. 2012 Jan-Feb;66(1):20-7
references: 22307659
references: J Am Pharm Assoc (Wash). 2002 Mar-Apr;42(2):195-9
references: 11926662
references: J Clin Psychiatry. 2004;65 Suppl 5:7-12
references: 15078112
references: Arch Pharm Res. 2011 Jul;34(7):1183-9
references: 21811926
references: Int J Pharm Compd. 2010 May-Jun;14(3):257-60
references: 23965504
references: J Manag Care Pharm. 2009 Apr;15(3):253-61
references: 19326956
references: Ann Pharmacother. 2002 Feb;36(2):205-9
references: 11847935
references: Eur J Pharm Biopharm. 2002 Mar;53(2):139-45
references: 11879995
references: J Am Pharm Assoc (2003). 2004 Sep-Oct;44(5):583-6
references: 15496044
references: J Manag Care Pharm. 2003 Sep-Oct;9(5):401-7
references: 14613437
references: J Am Pharm Assoc (Wash). 2002 Mar-Apr;42(2):200-5
references: 11926663